Jack Kaye Acquires Shares in uniQure N.V.

On June 17, 2026, Jack Kaye made a significant purchase of uniQure N.V. (NasdaqGS: QURE) shares. He acquired 5,295 shares at an average price of $31.71, totaling approximately $167,904. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at uniQure N.V.

Several insider transactions occurred around the same period. Jack Kaye also sold 5,295 shares at a price of $42.57 in a planned transaction on the same day. Additionally, Madhavan Balachandran bought 10,000 shares on June 15, 2026, at $8.49 and sold the same amount at a non-disclosed price. Jeannette Potts, Chief Legal Officer, sold 5,237 shares at $27.67 on June 15, 2026.

Other Institutional Activity in uniQure N.V.

Several institutional investors have been adjusting their positions in uniQure. AVORO CAPITAL ADVISORS LLC reduced its holdings by 190,405 shares, ending with 5,959,595 shares valued at around $97.44 million. Meanwhile, ABERDEEN GROUP PLC increased its stake by 1,627,746 shares, bringing its total to 5,306,386 shares worth approximately $86.76 million. TWO SIGMA INVESTMENTS, LP also boosted its position significantly by 1,224,587 shares, resulting in 2,675,871 shares valued at about $43.75 million.

uniQure N.V. Stock Down 6.1%

Shares of uniQure N.V. traded near $46.37 on Monday. The biotechnology company has a market capitalization of approximately $2.92 billion. It is currently not profitable, as indicated by its negative forward P/E ratio of -15.58. The stock's beta is 1.001, suggesting average market volatility. Over the past year, the stock has ranged from a low of $8.73 to a high of $71.50, with recent moving averages at $24.13 for 50 days and $27.53 for 200 days.

Analysts Set New Price Targets

On June 18, 2026, Barclays upgraded uniQure N.V. to a 'buy' with a price target of $65. Goldman Sachs maintained a 'hold' rating, setting a target of $46, while Leerink Partners and RBC Capital both maintained 'buy' ratings with targets of $70 and $65, respectively. The consensus among 11 analysts is a 'strong buy,' with a mean target price of $58.75.

About uniQure N.V.

uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focused on developing gene therapies for rare and severe diseases. Its flagship product, HEMGENIX, helps hemophilia B patients produce factor IX. Other notable projects include AMT-130 for Huntington's disease and various therapies in clinical trials for conditions like epilepsy and ALS. The company is led by CEO Matthew Craig Kapusta and employs 221 people.

Bottom Line

Jack Kaye's recent purchase of uniQure shares highlights ongoing interest in the company's potential. Investors and analysts alike are watching the biotech firm closely, particularly given its innovative treatments in development. As always, it's important to note that insider transactions are part of regular market activities and may not reflect future company performance.